Leadership changeRegulatory filing
What was reported
On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs of Nexalin Technology, Inc. (the “Company”).U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Sep 2, 2026 · Open the source ↗
What the evidence supports
Nexalin Technology told the SEC (Form 8-K, Item 5.02) that there was a change involving its directors or officers, or their pay arrangements. The filing gives Aug 28, 2026 as the date of the earliest event reported.
What remains unknown
The reasons for the change beyond those stated, and what it means for the company's strategy or results.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $20,000 | “In connection with her departure, Ms. Shelton and the Company entered into a separation agreement, which provides for one month of continued base salary, a 2026 bonus of $20,000, accelerated vesting of her unvested stock options, up to two years to exercise her vested options, and continued subsidy of her health insurance premiums through September 30, 2026.” |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.02 textOn August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs of Nexalin Technology, Inc. (the “Company”).U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Sep 2, 2026 · Open the source ↗
Amount stated in the filingIn connection with her departure, Ms. Shelton and the Company entered into a separation agreement, which provides for one month of continued base salary, a 2026 bonus of $20,000, accelerated vesting of her unvested stock options, up to two years to exercise her vested options, and continued subsidy of her health insurance premiums through September 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Sep 2, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Nexalin Technology reports changes involving its directors or officers (Form 8-K, Item 5.02)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.